Literature DB >> 8180330

European consensus statement on the prevention of venous thromboembolism. European Consensus Conference, Windsor, U.K., November, 1991.

S Haas1.   

Abstract

Since the Consensus Conference of the National Institute of Health in 1986, the developments in the field of prevention of venous thromboembolism were mainly characterized by a more specific and extended use of new prophylactic agents such as low molecular weight heparins as well as the perception that outpatients may be at risk for thromboembolic complications, too. Therefore, in November 1991, a European Consensus Conference on the prevention of thromboembolism was held in Windsor, UK, in order to analyse the risk constellation of various patient populations and to give recommendations for primary prophylaxis in general surgery, urology, neurosurgery, orthopaedic and trauma surgery, obstetrics and gynaecology and medical patients. In addition, the cost-effectiveness of the various methods was highlighted, and the question of secondary prevention addressed. The meeting was organized under the patronage of the European Economic Commission, and experts from 15 different countries were invited to participate. The conference was organized according to acknowledged guidelines of consensus conference organization, i.e. each expert had to formulate his provisional standpoint, the working documents were compiled by the organizer, and this file was sent to the delegates before the conference. During the first part of the meeting, the delegates presented their views in plenary sessions. Controversial points were discussed in working groups, and the results were discussed in plenary sessions. Consensus or lack of accord was documented and the open questions were formulated in order to be answered by future studies. The published statements and recommendations are based on different levels of evidence.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8180330

Source DB:  PubMed          Journal:  Blood Coagul Fibrinolysis        ISSN: 0957-5235            Impact factor:   1.276


  6 in total

Review 1.  Thrombophilia and the surgeon.

Authors:  E G Rhodes
Journal:  Ann R Coll Surg Engl       Date:  1996-07       Impact factor: 1.891

Review 2.  Reviparin: a review of its efficacy in the prevention and treatment of venous thromboembolism.

Authors:  K Wellington; K McClellan; B Jarvis
Journal:  Drugs       Date:  2001       Impact factor: 9.546

Review 3.  Clinical experience with bemiparin.

Authors:  José Ignacio Abad Rico; Francisco S Lozano Sánchez; Eduardo Rocha
Journal:  Drugs       Date:  2010-12-14       Impact factor: 9.546

4.  Effectiveness and safety of bemiparin versus low-molecular weight heparins in orthopaedic surgery.

Authors:  R Ferriols-Lisart; F Ferriols-Lisart; V Jiménez-Torres
Journal:  Pharm World Sci       Date:  2002-06

5.  Postoperative nadroparin administration for prophylaxis of thromboembolic events is not associated with an increased risk of hemorrhage after spinal surgery.

Authors:  Rüdiger Gerlach; Andreas Raabe; Jürgen Beck; Alina Woszczyk; Volker Seifert
Journal:  Eur Spine J       Date:  2003-11-13       Impact factor: 3.134

6.  Benefits and risks of low molecular weight heparin in patients with acute exacerbation of chronic obstructive pulmonary disease: a meta-analysis of randomized controlled trials.

Authors:  Mingjin Yang; Ying Xu; Hong Chen; Zhibo Xu; Fengming Luo
Journal:  Inflammopharmacology       Date:  2019-10-31       Impact factor: 4.473

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.